AbbVie: SKYRIZI® Hits Positive Phase 3 Goals in Crohn’s
AbbVie Reports Positive Phase 3 Results for Subcutaneous SKYRIZI® in Crohn’s Disease AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating…
Wisdom Bioscience Forms Scientific Advisory Board to Advance Oral Cancer Diagnostics
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening Wisdom Bioscience, a biotechnology company revolutionizing oral cancer diagnostics, has announced the formation of its Scientific Advisory…
FDA Accepts Takeda and Protagonist’s NDA for Rusfertide, a First-in-Class Treatment for Polycythemia Vera
Pivotal Study Shows Significant Improvements in Hematocrit Control and Patient Outcomes What does the future hold for patients with polycythemia vera (PV)? Takeda and Protagonist Therapeutics, Inc. have announced a…
Genentech’s Fenebrutinib Shows Significant Efficacy in Relapsing Multiple Sclerosis
Genentech Announces Positive Phase III Results for Fenebrutinib in RMS, Paving the Way for Regulatory Submission Why is the search for effective treatments for multiple sclerosis (MS) more urgent than…
Novocure to Showcase Tumor Treating Fields at Leerink Global Healthcare Conference
Novocure’s Leadership to Highlight Innovative Cancer Therapy at Prestigious Event Why should healthcare investors and oncology professionals be paying attention to Novocure’s upcoming participation in the Leerink Global Healthcare Conference?…
Cryo-Cell International Reports Fiscal 2025 Results: Revenue Declines, Net Loss Recorded
Cryo-Cell International Sees Revenue Dip and Net Loss in Fiscal 2025 What does a year of financial downturn mean for the world’s first private cord blood bank? Cryo-Cell International, Inc.…
Guardant Health Grants Equity Awards to New Non-Executive Employees
Strategic Equity Incentives to Attract Talent and Drive Innovation Why is attracting and retaining top talent crucial for precision oncology companies? Guardant Health, a leading precision oncology company, is taking…
Prothena Authorizes $100M Share Repurchase Plan to Enhance Shareholder Value
Prothena’s Strategic Move to Boost Shareholder Confidence and Financial Flexibility Why are biotechnology companies increasingly turning to share repurchase plans to optimize their financial strategies? Prothena Corporation plc, a late-stage…
Bayer Advances 225Ac-PSMA-Trillium for Metastatic Prostate Cancer
New Data Supports Next-Phase Development of Targeted Alpha Therapy Why is the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) so challenging? Despite significant advances, the prognosis for men with…
Natera’s Signatera MRD Advances Bladder Cancer Treatment and Patient Outcomes
New Data at ASCO GU Highlights Signatera’s Role in Bladder Preservation and Precision Medicine Why are precision medicine tools crucial for improving patient outcomes in genitourinary cancers? Natera, a global…
Pfizer and Astellas Announce Breakthrough in Muscle-Invasive Bladder Cancer Treatment
Positive Phase 3 Trial Results Signal New Standard of Care for Bladder Cancer Patients Is the current standard of care for muscle-invasive bladder cancer (MIBC) about to change? Pfizer Inc.…
Merck’s KEYTRUDA Plus Padcev Significantly Extends Survival in Bladder Cancer
New Combination Therapy Demonstrates 47% Reduction in Event-Free Survival Events Why is this a game-changer for bladder cancer treatment? Merck, a global leader in healthcare, has announced groundbreaking results from…